# Humacyte (HUMA) — News

HUMA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/huma/news

## Recent headlines

- [Humacyte Inc: Commercial sales accelerated as new hospital ordering activity increased sequentially each month of Q3](https://www.ainvest.com/news/humacyte-commercial-sales-accelerated-hospital-ordering-activity-increased-sequentially-month-q3-2610) — AInvest Wire, Oct 15, 2026
  Humacyte Inc. (Nasdaq: HUMA) has reported continued growth in commercial sales of its bioengineered vascular tissue product, Symvess™, driven by increasing hospital adoption and ordering activity. In Q3 2025, the company observed a sequential rise in new hospital orders each month, reflecting…
- [Humacyte: Symwess hospital orders rise 44% in 3Q](https://www.ainvest.com/news/humacyte-symwess-hospital-orders-rise-44-3q-2610) — AInvest Wire, Oct 15, 2026
- [Humacyte provides commercial update and highlights rapid acceleration of SymVess adoption by hospitals](https://www.ainvest.com/news/humacyte-commercial-update-highlights-rapid-acceleration-symvess-adoption-hospitals-2610) — AInvest Wire, Oct 15, 2026
  Humacyte, Inc. (Nasdaq: HUMA) has reported a rapid adoption of its FDA-approved Symvess product by hospitals across the United States. Symvess, an acellular tissue-engineered vessel, was granted full approval by the U.S. Food and Drug Administration (FDA) on December 19, 2024, for use in adults as…
- [Humacite announces phase 3 V012 trial results for Atev in women requiring hemodialysis access accepted for a late-breaking session presentation at ASN Kidney Week 2026](https://www.ainvest.com/news/humacite-announces-phase-3-v012-trial-results-atev-women-requiring-hemodialysis-access-accepted-late-breaking-session-presentation-asn-kidney-week-2026-2610) — AInvest Wire, Oct 12, 2026
- [Humacyte expands board expertise with appointment of Scott Coward and Paul Kuznik](https://www.ainvest.com/news/humacyte-expands-board-expertise-appointment-scott-coward-paul-kuznik-2609) — AInvest Wire, Sep 28, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).